These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 10700588)

  • 1. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.
    Houser SJ; Eads M; Embrey JP; Welch SP
    Brain Res; 2000 Feb; 857(1-2):337-42. PubMed ID: 10700588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.
    Pugh G; Mason DJ; Combs V; Welch SP
    J Pharmacol Exp Ther; 1997 May; 281(2):730-7. PubMed ID: 9152379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
    Welch SP; Dunlow LD; Patrick GS; Razdan RK
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.
    Mason DJ; Lowe J; Welch SP
    Eur J Pharmacol; 1999 Aug; 378(3):237-48. PubMed ID: 10493099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems.
    Welch SP
    Drug Alcohol Depend; 1997 Apr; 45(1-2):39-45. PubMed ID: 9179505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interactions of endogenous opioids and cannabinoid systems.
    Welch SP; Eads M
    Brain Res; 1999 Nov; 848(1-2):183-90. PubMed ID: 10612710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
    Welch SP; Huffman JW; Lowe J
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats.
    Smith FL; Fujimori K; Lowe J; Welch SP
    Pharmacol Biochem Behav; 1998 May; 60(1):183-91. PubMed ID: 9610941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
    Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
    J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
    Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
    Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynorphin-independent spinal cannabinoid antinociception.
    Gardell LR; Ossipov MH; Vanderah TW; Lai J; Porreca F
    Pain; 2002 Dec; 100(3):243-248. PubMed ID: 12467995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta.
    O'Sullivan SE; Kendall DA; Randall MD
    Eur J Pharmacol; 2005 Jan; 507(1-3):211-21. PubMed ID: 15659311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM; Wakley AA; Tsutsui KT; Laggart JD
    J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex-specific mechanisms of tolerance for the cannabinoid agonists CP55,940 and delta-9-tetrahydrocannabinol (Δ
    Henderson-Redmond AN; Sepulveda DE; Ferguson EL; Kline AM; Piscura MK; Morgan DJ
    Psychopharmacology (Berl); 2022 May; 239(5):1289-1309. PubMed ID: 34165606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord.
    Pugh G; Smith PB; Dombrowski DS; Welch SP
    J Pharmacol Exp Ther; 1996 Nov; 279(2):608-16. PubMed ID: 8930163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure.
    Burkey RT; Nation JR
    Exp Clin Psychopharmacol; 1997 Aug; 5(3):195-202. PubMed ID: 9260067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice.
    Smith PB; Compton DR; Welch SP; Razdan RK; Mechoulam R; Martin BR
    J Pharmacol Exp Ther; 1994 Jul; 270(1):219-27. PubMed ID: 8035318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors.
    Xiong W; Wu X; Li F; Cheng K; Rice KC; Lovinger DM; Zhang L
    J Neurosci; 2012 Apr; 32(15):5200-8. PubMed ID: 22496565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ontogenetic development of the response to anandamide and delta 9-tetrahydrocannabinol in mice.
    Fride E; Mechoulam R
    Brain Res Dev Brain Res; 1996 Aug; 95(1):131-4. PubMed ID: 8873985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
    Pertwee RG; Stevenson LA; Griffin G
    Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.